#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Raynaud's phenomenon


Authors: Michal Tomčík
Authors‘ workplace: Revmatologický ústav a Revmatologická klinika 1. LF UK
Published in: Čas. Lék. čes. 2016; 155: 310-318
Category: Review Article

Overview

Raynaud's phenomenon (RP) is a very common sign which can usually be seen across all medical specialties. It is characterized by episodic color changes of acral parts of the body (palor, cyanosis, rubor) lasting from a few minutes to hours, which are usually triggered by cold temperature and/or stress. The primary RP occurs alone, without concomitant diseases, is usually benign and has favorable prognosis. Secondary RP occurs in a variety of diseases with a very variable progression and prognosis, mostly unfavorable one due to the development of ischemic tissue necrosis and gangrene. This work provides a comprehensive overview of the history, current knowledge about the epidemiology and pathogenesis and the recommended evaluation and treatment of RP.

Keywords:
Raynaud's phenomenon, primary, secondary, capillaroscopy, treatment


Sources

1. Wigley FM. Clinical practice. Raynaud’s Phenomenon. N Engl J Med 2002; 347(13): 1001–1008.

2. Hughes M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol 2016; 30(1): 112–132.

3. Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol 2015; 11(3): 146–158.

4. Cappelli L, Wigley FM. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma. Rheum Dis Clin North Am 2015; 41(3): 419–438.

5. Raynaud M. De l’asphyxie locale et de la gangrene symetrique des extremites. Thesis. L. Leclerc, Libraire-Editeur, Paris, 1862.

6. Hutchinson J. Raynaud’s phenomena. Med Press Circ 1901; 123: 402–405.

7. Allen EV, Brown GE. Raynaud’s disease: a critical review of minimal requisities for diagnosis. Am J Med Sci 1932; 183: 187–200.

8. LeRoy EC, Medsger TA jr. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10(5): 485–488.

9. Maverakis E, Patel F, Kronenberg DG et al. International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 2014; 48–49: 60–65.

10. Riera G, Vilardell M, Vaque J et al. Prevalence of Raynaud’s phenomenon in a healthy Spanish population. J Rheumatol 1993; 20(1): 66–69.

11. De Angelis R, Salaffi F, Grassi W. Raynaud’s phenomenon: prevalence in an Italian population sample. Clin Rheumatol 2006; 25(4): 506–510.

12. Onbasi K, Sahin I, Onbasi O et al. Raynaud’s phenomenon in a healthy Turkish population. Clin Rheumatol 2005; 24(4): 365–369.

13. Brand FN, Larson MG, Kannel WB et al. The occurrence of Raynaud’s phenomenon in a general population: the Framingham Study. Vasc Med 1997; 2(4): 296–301.

14. Purdie G, Harrison A, Purdie D. Prevalence of Raynaud’s phenomenon in the adult New Zealand population. N Z Med J 2009; 122(1306): 55–62.

15. Silman A, Holligan S, Brennan P et al. Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ 1990; 301(6752): 590–592.

16. Suter LG, Murabito JM, Felson DT et al. The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum 2005; 52(4): 1259–1263.

17. Planchon B, Pistorius MA, Beurrier P et al. Primary Raynaud’s phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45(8): 677–686.

18. Fraenkel L. Raynaud’s phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002; 4(2): 123–128.

19. Keil JE, Maricq HR, Weinrich MC et al. Demographic, social and clinical correlates of Raynaud phenomenon. Int J Epidemiol 1991; 20(1): 221–224.

20. Fraenkel L, Zhang Y, Chaisson CE et al. Different factors influencing the expression of Raynaud’s phenomenon in men and women. Arthritis Rheum 1999; 42(2): 306–310.

21. Maricq HR, Carpentier PH, Weinrich MC et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 1997; 24(5): 879–889.

22. Maricq HR, Carpentier PH, Weinrich MC et al. Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20(1): 70–76.

23. Purdie GL, Purdie DJ, Harrison AA. Raynaud’s phenomenon in medical laboratory workers who work with solvents. J Rheumatol 2011; 38(9): 1940–1946.

24. Freedman RR, Mayes MD. Familial aggregation of primary Raynaud’s disease. Arthritis Rheum 1996; 39(7): 1189–1191.

25. Smyth AE, Hughes AE, Bruce IN et al. A case-control study of candidate vasoactive mediator genes in primary Raynaud’s phenomenon. Rheumatology (Oxford) 1999; 38(11): 1094–1098.

26. Cherkas LF, Williams FM, Carter L et al. Heritability of Raynaud’s phenomenon and vascular responsiveness to cold: a study of adult female twins. Arthritis Rheum 2007; 57(3): 524–528.

27. Pope JE. Raynaud’s phenomenon (primary). BMJ Clin Evid 2011; 2011.

28. Hirschl M, Kundi M. Initial prevalence and incidence of secondary Raynaud’s phenomenon in patients with Raynaud’s symptomatology. J Rheumatol 1996; 23(2): 302–309.

29. Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16(5): 454–460.

30. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66(6): 754–763.

31. Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud’s syndrome with rheumatoid arthritis – a meta-analysis. Clin Rheumatol 2011; 30(8): 1013–1019.

32. Lin DF, Yan SM, Zhao Y et al. Clinical and prognostic characteristics of 573 cases of primary Sjogren's syndrome. Chin Med J (Engl) 2010; 123(22): 3252–3257.

33. Gronhagen CM, Gunnarsson I, Svenungsson E et al. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus 2010; 19(10): 1187–1194.

34. Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996–2009. Clin Rheumatol 2010; 29(12): 1381–1385.

35. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011; 37(1): 100–109.

36. Grader-Beck T, Wigley FM. Raynaud’s phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31(3): 465–481, vi.

37. De Angelis R, Cerioni A, Del Medico P et al. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol 2005; 24(2): 145–151.

38. Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud syndrome with thromboangiitis obliterans – a meta-analysis. Angiology 2012; 63(4): 315–319.

39. Monti G, Galli M, Invernizzi F et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88(2): 115–126.

40. Soyfoo MS, Goubella A, Cogan E et al. Clinical significance of Cryofibrinogenemia: possible pathophysiological link with Raynaud’s phenomenon. J Rheumatol 2012; 39(1): 119–124.

41. Saadoun D, Elalamy I, Ghillani-Dalbin P et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122(12): 1128–1135.

42. Knapik-Kordecka M, Wysokinski WE. Clinical spectrum of Raynaud’s phenomenon in patients referred to vascular clinic. Cardiovasc Surg 2000; 8(6): 457–462.

43. Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud’s syndrome with carpal tunnel syndrome: a meta-analysis. Rheumatol Int 2012; 32(3): 569–574.

44. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol 2007; 13(48): 6518–6528.

45. Rogeaux O, Fassin D, Gentilini M. [Prevalence of rheumatic manifestations in human immunodeficiency virus infection]. Ann Med Interne (Paris) 1993; 144(7): 443–448.

46. Bovenzi M. A follow up study of vascular disorders in vibration-exposed forestry workers. Int Arch Occup Environ Health 2008; 81(4): 401–408.

47. Letz R, Cherniack MG, Gerr F et al. A cross sectional epidemiological survey of shipyard workers exposed to hand-arm vibration. Br J Ind Med 1992; 49(1): 53–62.

48. Cooke RA. Hypothenar hammer syndrome: a discrete syndrome to be distinguished from hand-arm vibration syndrome. Occup Med (Lond) 2003; 53(5): 320–324.

49. Marie I, Herve F, Primard E et al. Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients. Medicine (Baltimore) 2007; 86(6): 334–343.

50. Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud’s syndrome with cisplatin-based chemotherapy – a meta-analysis. Eur J Intern Med 2012; 23(7): 594–598.

51. Vogelzang NJ, Bosl GJ, Johnson K et al. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95(3): 288–292.

52. Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud syndrome with beta-blockers: a meta-analysis. Angiology 2012; 63(7): 535–540.

53. Mohokum M, Hartmann P, Schlattmann P. Association of Raynaud’s syndrome with interferons. A meta-analysis. Int Angiol 2012; 31(5): 408–413.

54. Nielsen SL, Parving HH, Hansen JE. Myxoedema and Raynaud’s phenomenon. Acta Endocrinol (Copenh) 1982; 101(1): 32–34.

55. Shen M, Zhang F, Zhang X. Pulmonary hypertension in primary biliary cirrhosis: a prospective study in 178 patients. Scand J Gastroenterol 2009; 44(2): 219–223.

56. Miest RY, Comfere NI, Dispenzieri A et al. Cutaneous manifestations in patients with POEMS syndrome. Int J Dermatol 2013; 52(11): 1349–1356.

57. Koenig M, Joyal F, Fritzler MJ et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58(12): 3902–3912.

58. Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ et al. Late appearance and exacerbation of primary Raynaud’s phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients. Rheumatol Int 2013; 33(4): 921–926.

59. Hirschl M, Hirschl K, Lenz M et al. Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54(6): 1974–1981.

60. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158(6): 595–600.

61. Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum 2007; 56(6): 2102–2103; author reply 2103–2104.

62. Bartelink ML, De Wit A, Wollersheim H et al. Skin vascular reactivity in healthy subjects: influence of hormonal status. J Appl Physiol (1985) 1993; 74(2): 727–732.

63. Bergersen TK, Eriksen M, Walloe L. Local constriction of arteriovenous anastomoses in the cooled finger. Am J Physiol 1997; 273(3 Pt 2): R880–886.

64. Bollinger A, Schlumpf M. Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud’s disease. Acta Chir Scand Suppl. 1976; 465: 42–47.

65. Braverman IM. The cutaneous microcirculation. J Investig Dermatol Symp Proc 2000; 5(1): 3–9.

66. Cankar K, Finderle Z, Strucl M. The role of alpha1- and alpha2-adrenoceptors in gender differences in cutaneous LD flux response to local cooling. Microvasc Res 2004; 68(2): 126–131.

67. Carter SA, Dean E, Kroeger EA. Apparent finger systolic pressures during cooling in patients with Raynaud’s syndrome. Circulation 1988; 77(5): 988–996.

68. Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud’s phenomenon. N Engl J Med 1971; 285(5): 259–263.

69. Coffman JD. Pathogenesis and treatment of Raynaud’s phenomenon. Cardiovasc Drugs Ther 1990; 4(Suppl. 1): 45–51.

70. Cooke JP, Creager SJ, Scales KM et al. Role of digital artery adrenoceptors in Raynaud’s disease. Vasc Med 1997; 2(1): 1–7.

71. Dorffler-Melly J, Luscher TF, Wenk M et al. Endothelin-1 and cold provocation in health, primary Raynaud’s phenomenon, and progressive systemic sclerosis. Microvasc Res 1996; 52(2): 193–197.

72. Fagius J, Blumberg H. Sympathetic outflow to the hand in patients with Raynaud’s phenomenon. Cardiovasc Res 1985; 19(5): 249–253.

73. Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010; 6(10): 578–587.

74. Cutolo M, Ferrone C, Pizzorni C et al. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J Rheumatol 2010; 37(6): 1174–1180.

75. Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993; 84(4): 675–680.

76. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 2005; 44(5): 587–596.

77. Brennan P, Silman A, Black C et al. Validity and reliability of three methods used in the diagnosis of Raynaud’s phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 1993; 32(5): 357–361.

78. Linnemann B, Erbe M. Raynauds phenomenon – assessment and differential diagnoses. Vasa 2015; 44(3): 166–177.

79. Bartelink ML, Wollersheim H, Leesmans E et al. A standardized finger cooling test for Raynaud’s phenomenon: diagnostic value and sex differences. Eur Heart J 1993; 14(5): 614–622.

80. Lau CS, Khan F, Brown R et al. Digital blood flow response to body warming, cooling, and rewarming in patients with Raynaud’s phenomenon. Angiology 1995; 46(1): 1–10.

81. Ring EF. Quantitative thermal imaging. Clin Phys Physiol Meas 1990; 11 Suppl A: 87–95.

82. Briers JD. Laser Doppler, speckle and related techniques for blood perfusion mapping and imaging. Physiol Meas 2001; 22(4): R35–66.

83. Seifalian AM, Stansby G, Jackson A et al. Comparison of laser Doppler perfusion imaging, laser Doppler flowmetry, and thermographic imaging for assessment of blood flow in human skin. Eur J Vasc Surg 1994; 8(1): 65–69.

84. Toprak U, Hayretci M, Erhuner Z et al. Dynamic Doppler evaluation of the hand arteries to distinguish between primary and secondary raynaud phenomenon. Am J Roentgenol 2011; 197(1): W175–180.

85. Hahn M, Hahn C, Junger M et al. Local cold exposure test with a new arterial photoplethysmographic sensor in healthy controls and patients with secondary Raynaud’s phenomenon. Microvasc Res 1999; 57(2): 187–198.

86. Kim YH, Ng SW, Seo HS et al. Classification of Raynaud’s disease based on angiographic features. J Plast Reconstr Aesthet Surg 2011; 64(11): 1503–1511.

87. Allanore Y, Seror R, Chevrot A et al. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 2007; 56(8): 2747–2754.

88. Jens S, Koelemay MJ, Reekers JA et al. Diagnostic performance of computed tomography angiography and contrast-enhanced magnetic resonance angiography in patients with critical limb ischaemia and intermittent claudication: systematic review and meta-analysis. Eur Radiol 2013; 23(11): 3104–3114.

89. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72(11): 1747–1755.

90. Bellando-Randone S, Matucci-Cerinic M. From Raynaud’s phenomenon to very early diagnosis of systemic sclerosis – The VEDOSS approach. Curr Rheumatol Rev 2013; 9(4): 245–248.

91. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012; 8(8): 469–479.

92. Ennis H, Hughes M, Anderson ME et al. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev 2016; 2: CD002069.

93. Pope J. Raynaud’s phenomenon (primary). BMJ Clin Evid 2013; 2013: 1119.

94. Stewart M, Morling JR. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst Rev 2012(7): CD006687.

95. Roustit M, Hellmann M, Cracowski C et al. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud’s phenomenon. Clin Pharmacol Ther 2012; 91(5): 813–819.

96. Pauling JD, O'Donnell VB, McHugh NJ. The contribution of platelets to the pathogenesis of Raynaud’s phenomenon and systemic sclerosis. Platelets 2013; 24(7): 503–515.

97. Cairoli E, Rebella M, Danese N et al. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012; 21(11): 1178–1182.

98. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 2008; 35(9): 1801–1808.

99. Nguyen VA, Eisendle K, Gruber I et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 2010; 49(3): 583–587.

100. Belch JJ, Newman P, Drury JK et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. A double-blind controlled trial. Lancet 1983; 1(8320): 313–315.

101. Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000(2): CD000953.

102. Bartolone S, Trifiletti A, De Nuzzo G et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol 1999; 47(5): 137–143.

103. Hashem M, Lewis R. Successful long-term treatment of a patient with long-standing Raynaud’s disease by an extradural bupivacaine block. Anaesth Intensive Care 2007; 35(4): 618–619.

104. Claes G, Drott C, Gothberg G. Thoracoscopic sympathicotomy for arterial insufficiency. Eur J Surg Suppl 1994(572): 63–64.

105. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003; 30(8): 1788–1792.

106. Bank J, Fuller SM, Henry GI et al. Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality. Plast Reconstr Surg 2014; 133(5): 1109–1118. 

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#